Cidara is a clinical-stage biotechnology company focused on the development of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.
Cidara News + Events
Cidara CEO Jeffrey Stein, Ph.D., Discusses Rezafungin and Antiviral Fc-Conjugates on the Contagion Connect Podcast
There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly for today’s increasingly complex and immunocompromised patients.
Our initial portfolio is comprised of proprietary product and development candidates for the treatment and prevention of serious infections.